secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059097
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE
----------------------------------------------------------------

- Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.
- ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive patients (10) vs 0% in negative (16), p=0.0038.
- Endometrial cancer identified as new AP3-predicted sensitive tumor type; median DoR not yet reached.
- ACR-2316 IND expected Q3 2024; Phase 1 start Q4 2024.
- Closed oversubscribed $130M private placement at premium; cash ~$240M pro forma into H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/0000950170-24-059097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/acrv-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer